Drug loaded nanomaterials for hematological malignancies diagnosis and enhanced targeted therapy

Samal, Priyanka; Begum, Shahani

doi:10.1016/b978-0-323-85725-3.00016-7

Cited by 4 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the currently available anticancer drugs are limited in their safety and efficacy. Successful cancer therapy depends on its preferential wipeout of cancer cells without side effects or negligible toxicity to the normal cells [35,36].…”

Section: Need For Alternative Drugs To Treat Cancer and Microbial Inf...mentioning

confidence: 99%

Antimicrobial and anticancer potential of soil bacterial metabolites - a comprehensive and updated review

Kumar¹,

Kumaresan²

2023

J App Biol Biotech

View full text Add to dashboard Cite

The majority of natural products currently used in the medical field are derived from microbial or plant sources. The bioactive compounds derived from natural sources exhibit tremendous structural and chemical diversity. According to previous research, only a small percentage of the world's plant and microbial diversity has been examined for bioactivities. The compounds originating from secondary metabolites of microorganisms are more useful for the development of novel drugs due to their biological friendliness and drug-likeness than any other compounds. Thus, recent research suggests that microorganisms obtained from diverse habitats and natural resources offer various bioactive secondary metabolites with incredibly wider chemical entities, hopefully, an alternative remedy for many diseases. Soil bacteria are capable of producing a variety of natural bioactive compounds for the treatment of various diseases. The three genera Bacillus spp., Streptomyces spp., and Pseudomonas spp. have been the prime focus to produce different types of antibiotics. However, to date, there are no reviews that evaluated the antimicrobial and anticancer properties of soil bacterial metabolites. Hence, the current review aimed to assess the antimicrobial and anticancer potential of soil bacterial metabolites.

show abstract

Section: Need For Alternative Drugs To Treat Cancer and Microbial Inf...mentioning

confidence: 99%

Antimicrobial and anticancer potential of soil bacterial metabolites - a comprehensive and updated review

Kumar¹,

Kumaresan²

2023

J App Biol Biotech

View full text Add to dashboard Cite

show abstract

“…Hematologic malignancies, comprising approximately one-third of all cancers worldwide, originate from abnormal differentiation or mutations of hematopoietic stem cells in bone marrow. , Radiation, chemotherapy and/or stem cell transplantation remain the mainstay of blood cancer treatment. However, these treatment modalities are often characterized by low therapeutic indices, poor bioavailability, high-dose requirements, and significant healthy tissue toxicity. − To overcome these drawbacks, molecularly targeted drugs have emerged as an appealing alternative.…”

Section: Introductionmentioning

confidence: 99%

Targeted Lymphoma Therapy Using a Gold Nanoframework-Based Drug Delivery System

Bariana

Zhang

Sun

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Precision nanomedicine can be employed as an alternative to chemo-or radiotherapy to overcome challenges associated with the often narrow therapeutic window of traditional treatment approaches, while safely inducing effective, targeted antitumor responses. Herein, we report the formulation of a therapeutic nanocomposite comprising a hyaluronic acid (HA)coated gold nanoframework (AuNF) delivery system and encapsulated IT848, a small molecule with potent antilymphoma and -myeloma properties that targets the transcriptional activity of nuclear factor kappa B (NF-κB). The porous AuNFs fabricated via a liposome-templated approach were loaded with IT848 and surfacefunctionalized with HA to formulate the nanotherapeutics that were able to efficiently deliver the payload with high specificity to myeloma and lymphoma cell lines in vitro. In vivo studies characterized biodistribution, pharmacokinetics, and safety of HA-AuNFs, and we demonstrated superior efficacy of HA-AuNF-formulated IT848 vs free IT848 in lymphoma mouse models. Both in vitro and in vivo results affirm that the AuNF system can be adopted for targeted cancer therapy, improving the drug safety profile, and enhancing its efficacy with minimal dosing. HA-AuNF-formulated IT848 therefore has strong potential for clinical translation.

show abstract